Revolution Medicines, Inc. (NASDAQ:RVMD) received FDA approval for Rasonque, or daraxonrasib, following an expedited review.
Keep Reading →
September 4 - Hedge Funds, News
Incyte Corporation (NASDAQ:INCY) generated buzz on August 19 when RBC Capital highlighted upcoming ESMO data for its KRAS G12D inhibitor ‘734 in combination with mFOLFIRINOX...
Keep Reading →
August 28 - Hedge Funds, News
Revolution Medicines, Inc.
Keep Reading →
August 28 - News
Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc.
Keep Reading →
August 14 - Hedge Funds, News
Revolution Medicines (NASDAQ:RVMD) just picked up a partner with deep pockets and a presence across Asia.
Keep Reading →
August 11 - Hedge Funds, News
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here.
Keep Reading →
August 4 - Hedge Fund Investor Letters, News
In this article, we will discuss the 10 Best Hot Stocks to Buy for June.
Keep Reading →
June 12 - Hedge Funds, News
In this article, we will discuss the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller.
Keep Reading →
June 3 - Hedge Funds, News
Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best medical stocks to invest in according to billionaires. Truist assumed coverage of Revolution Medicines, Inc.
Keep Reading →
May 26 - News
In this article, we will look at the 12 Best Medical Stocks to Invest In According to Billionaires.
Keep Reading →
May 24 - Hedge Funds, News
Tom Steyer ranks among the list of the richest hedge fund managers in the world. Revolution Medicines, Inc.
Keep Reading →
May 20 - News
In this article, we will take a look at the 16 Richest Hedge Fund Managers in the World and their top stock picks.
Keep Reading →
May 18 - Hedge Funds, News
Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best performing healthcare stocks so far in 2026. Revolution Medicines, Inc.
Keep Reading →
May 10 - News
In this article, we will look at the 10 Best Performing Healthcare Stocks So Far in 2026.
Keep Reading →
May 8 - Hedge Funds, News
Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2026 Earnings Call Transcript May 6, 2026Revolution Medicines, Inc. misses on earnings expectations.
Keep Reading →
May 8 - News, Transcripts
In this article, we discuss the Billionaire Tom Steyer's Stock Picks with Huge Upside Potential.
Keep Reading →
April 30 - Hedge Funds, News
In this article, we will look at the 10 Best Stocks to Buy in a Rising Market According to Wall Street Analysts.
Keep Reading →
April 30 - Hedge Funds, News
In this article, we take a look at 12 Takeover Rumors Targeted By Short Sellers. Takeover chatter can lift a stock, but it does not force short sellers to leave.
Keep Reading →
April 20 - Hedge Funds, News
Ten stocks boasted strong double- to triple-digit gains last week, outperforming a mostly optimistic US market amid US and Iran’s efforts for a peace deal.
Keep Reading →
April 19 - Market Movers, News
In this article, we will discuss: Jim Cramer Discussed AI "Mojo" & Commented On These 13 Stocks.
Keep Reading →
April 17 - News
In this article, we take a look at 10 Potential Takeover Targets with Strong Price Momentum.
Keep Reading →
April 15 - Hedge Funds, News
Ten stocks kicked off the trading week with double-digit gains, with five notably reaching fresh record highs, thanks to a broader market optimism and positive corporate developments...
Keep Reading →
April 13 - Market Movers, News
We recently compiled a list of the 13 Best Stocks to Invest In on Robinhood for Beginners. Revolution Medicines, Inc. is one of the best Robinhood stocks.
Keep Reading →
March 30 - News
In this article, we will be taking a look at the 13 Best Stocks to Invest In on Robinhood for Beginners.
Keep Reading →
March 29 - Hedge Funds, News
Is RVMD a good stock to buy? We came across a bullish thesis on Revolution Medicines, Inc. on Two Natural Capital’s Substack.
Keep Reading →
March 29 - News, Stock Analysis
Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best cancer stocks to invest in now. On February 26, Revolution Medicines, Inc. (NASDAQ:RVMD) CEO Mark A.
Keep Reading →
March 2 - News
In this article, we will discuss the 11 Best Cancer Stocks to Invest In Now. Pharmaceutical companies are a blend of defensive income plays and growth opportunities.
Keep Reading →
February 28 - Hedge Funds, News
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2025 Earnings Call Transcript February 25, 2026Revolution Medicines, Inc. misses on earnings expectations.
Keep Reading →
February 27 - News, Transcripts
Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best strong buy healthcare stocks to invest in. Revolution Medicines, Inc.
Keep Reading →
February 26 - News
In this article, we will look at the 11 Best Strong Buy Healthcare Stocks to Invest In.
Keep Reading →
February 26 - Hedge Funds, News
Aristotle Funds, an investment advisor, released its “Growth Equity Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S.
Keep Reading →
February 26 - Hedge Fund Investor Letters, News
Revolution Medicines Inc. (NASDAQ:RVMD) is among the 15 Undervalued Momentum Stocks That Are Taking Off. JPMorgan added Overweight-rated Revolution Medicines Inc.
Keep Reading →
February 24 - News
“It seems like the momentum stocks that have got us here still remain in favor with our customers.” This was highlighted by Steve Sosnick, Chief Strategist at Interactive ...
Keep Reading →
February 23 - Hedge Funds, News
We recently published 10 Big Names Stumbling Hard. Revolution Medicines Inc. (NASDAQ:RVMD) was one of the worst performers on Monday.
Keep Reading →
January 27 - News
Jim Cramer, the host of Mad Money, told viewers on Tuesday that it may be time to lock in gains from stocks that have gone parabolic.
Keep Reading →
January 22 - Hedge Funds, News
We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Revolution Medicines, Inc. (NASDAQ:RVMD) was one of the top performers on Wednesday.
Keep Reading →
January 7 - News
Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2025 Earnings Call Transcript November 5, 2025Revolution Medicines, Inc. misses on earnings expectations.
Keep Reading →
November 7 - News, Transcripts
Jim Cramer, the host of Mad Money, on Thursday addressed the sharp downturn in markets driven by mounting concerns over deteriorating bank loans.
Keep Reading →
October 17 - Hedge Funds, News
Revolution Medicines, Inc. (NASDAQ:RVMD) is among the most promising biotech stocks to buy according to hedge funds.
Keep Reading →
October 2 - News
In this article, we will take a look at some of the most promising biotech stocks to buy according to hedge funds.
Keep Reading →
September 30 - Hedge Funds, News
Revolution Medicines, Inc. (NASDAQ:RVMD) ranks among the best mid-cap stocks with huge upside potential.
Keep Reading →
September 2 - News
In this article, we will take a look at the 12 Best Mid-Cap Stocks with Huge Upside Potential.
Keep Reading →
August 31 - Hedge Funds, News
In this article, we will look at the 13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds.
Keep Reading →
August 27 - Hedge Funds, News
Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the most promising future stocks according to Wall Street analysts.
Keep Reading →
August 22 - News
In this article, we will look at the 12 Most Promising Future Stocks According to Wall Street Analysts.
Keep Reading →
August 20 - Hedge Funds, News
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best upside stocks to invest in now.
Keep Reading →
August 13 - News
Earlier on July 17, Sharmin Mossavar-Rahmani, Goldman Sachs CIO of wealth management, joined 'Squawk Box' on CNBC to discuss the latest market trends, what to expect in H2 2025...
Keep Reading →
August 12 - Hedge Funds, News
Revolution Medicines, Inc. (NASDAQ:RVMD) Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Good day, and thank you for standing by.
Keep Reading →
August 8 - News, Transcripts
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best mid cap pharma stocks to buy.
Keep Reading →
July 25 - News
On July 14, Emily Field, the head of European pharma research at Barclays, appeared on CNBC to discuss which drug makers would be most impacted by 30% US tariffs on EU imports...
Keep Reading →
July 23 - Hedge Funds, News